Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Study Evaluating the Safety and Efficacy of MASCT-I Combined With Apatinib Mesylate and/or Camrelizumab in the Treatment of Patients With Advanced Bone and Soft Tissue Sarcoma

Next Previous
Trial Profile

An Exploratory Study Evaluating the Safety and Efficacy of MASCT-I Combined With Apatinib Mesylate and/or Camrelizumab in the Treatment of Patients With Advanced Bone and Soft Tissue Sarcoma

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 26 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; MASCT I (Primary) ; Rivoceranib (Primary)
  • Indications Alveolar soft part sarcoma; Clear cell sarcoma; Osteosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors HengRui YuanZheng Bio-Technology

Most Recent Events

  • 19 Oct 2023 Planned End Date changed from 5 Nov 2023 to 5 Dec 2024.
  • 19 Oct 2023 Planned primary completion date changed from 7 Oct 2023 to 7 Aug 2024.
  • 08 Oct 2023 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top